COMMUNIQUÉS West-GlobeNewswire

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
16/10/2026
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a [...]
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
16/10/2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
twiist™ Automated Insulin Delivery System is Now Cleared for Adults with Type 2 Diabetes
16/10/2026
Clearance expands twiist's precise insulin delivery and personalized automation to the largest population of people treated with insulin, with time-in-range improvements seen in as little as one day in a pivotal trial 1 [...]
Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
16/10/2026
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, [...]
hear.com Receives 2026 Global Recognition Award for Hearing Care Innovation
16/10/2026
Recognition honors hear.com’s Clinic-in-a-Box® teleaudiology platform and Horizon IX hearing aids for expanding access to personalized, medical-grade hearing care MIAMI, Oct. 16, 2026 (GLOBE NEWSWIRE) -- hear.com, an [...]
Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
16/10/2026
BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule [...]
Biomerica Reports First Quarter Fiscal 2027 Financial Results
16/10/2026
InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activity InFoods® IBS update: 100% of all [...]
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
16/10/2026
Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human [...]
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
16/10/2026
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
16/10/2026
New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB [...]
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
16/10/2026
PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of [...]
Hemp Hop Launches Mini Pre Rolls Collection as Cannabis Multipacks Gain Momentum
16/10/2026
CHARLOTTE, N.C., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Hemp Hop, a premium THCa Dispensary brand founded in Charlotte, North Carolina, in 2018, has announced the launch of its new Mini Pre Rolls collection introducing 7 [...]
NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
16/10/2026
Why Abu Dhabi Strategy and New Banking Director Signal Bigger Global Ambition DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human [...]
SafeSpace Global Extends Exclusive BMRT Security Agreement to Houses of Worship and Addiction Treatment Centers
16/10/2026
BMRT’s Base Molecular Resonance ™ Technology Detects the Molecular Signature of a Concealed Firearm from More Than 500 Feet Away and Identifies Drugs Inside Vehicles and Backpacks at a Distance; Expansion Adds More Than [...]
Breast Cancer Awareness Fundraiser with Prairie Cannabis
16/10/2026
Prairie Cannabis Launches Breast Cancer Awareness Fundraiser Supporting Gilda's Club Chicago Throughout October Illinois dispensary partners with nonprofit to provide free cancer support services during Breast Cancer [...]
Moleculin Announces Reverse Stock Split
16/10/2026
HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation [...]
Kexing Biopharm’s Biologics License Application for Long-Acting G-CSF Candidate GB-K02 Accepted for Review
16/10/2026
SAN DIEGO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kexing Biopharm (688136.SH) recently announced that it has received a Notice of Acceptance from China’s National Medical Products Administration (NMPA) for the biologics [...]
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
16/10/2026
If approved, TALVEY ® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line CHMP recommendation based on Phase 3 [...]

Pages